Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review

D M Adcock1, R Gosselin2

  • 1Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, United States.

Thrombosis Research
|May 19, 2015
PubMed

Insights

New direct oral anticoagulants (DOACs) offer potential benefits over warfarin. This review details their clinical use, mechanisms, and laboratory assay effects, including specialized testing for drug monitoring.

Area of Science:

  • Pharmacology
  • Clinical Chemistry
  • Hematology

Background:

  • Direct oral anticoagulants (DOACs) are emerging therapies for anticoagulation.
  • DOACs include direct anti-factor Xa and direct thrombin inhibitors.
  • These agents may offer advantages over traditional vitamin K antagonists like warfarin.

Purpose of the Study:

  • To review the clinical utility and mechanisms of action of DOACs.
  • To detail the impact of DOACs on routine and specialty laboratory coagulation assays.
  • To discuss methods for monitoring DOAC concentrations in laboratory settings.

Main Methods:

  • Literature review of clinical studies and laboratory investigations.
  • Analysis of the effects of DOACs on activated partial thromboplastin time (APTT) and prothrombin time (PT) assays.
  • Evaluation of drug-specific assays and alternative monitoring methods.

Main Results:

  • DOACs exhibit distinct effects on various coagulation assays.
  • Standard APTT and PT assays may not accurately reflect anticoagulation intensity with DOACs.
  • Drug-specific assays and calibrated anti-Xa assays are valuable for monitoring DOAC levels.

Conclusions:

  • Understanding DOAC effects on laboratory assays is crucial for accurate patient management.
  • Specialized testing and monitoring strategies are necessary for DOAC therapy.
  • DOACs represent a significant advancement in anticoagulant therapy requiring tailored laboratory support.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
680
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
444
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
317